Vanguard Group
VIR icon

Vanguard Group’s Vir Biotechnology VIR Stock Holding History

Vanguard Group’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$75.7M Sell
12,548,944
-250,437
-2% -$1.49M ﹤0.01% 1973
2025
Q3 		$73.1M Sell
12,799,381
-427,685
-3% -$2.19M ﹤0.01% 1982
2025
Q2 		$66.7M Buy
13,227,066
+419,558
+3% +$2.25M ﹤0.01% 2002
2025
Q1 		$83M Sell
12,807,508
-323,127
-2% -$2.87M ﹤0.01% 1872
2024
Q4 		$96.4M Sell
13,130,635
-5,321
-0% -$42K ﹤0.01% 1890
2024
Q3 		$98.4M Buy
13,135,956
+286,739
+2% +$2.49M ﹤0.01% 1879
2024
Q2 		$114M Buy
12,849,217
+473,862
+4% +$4.54M ﹤0.01% 1770
2024
Q1 		$125M Buy
12,375,355
+78,216
+0.6% +$797K ﹤0.01% 1747
2023
Q4 		$124M Buy
12,297,139
+1,096,473
+10% +$10M ﹤0.01% 1747
2023
Q3 		$105M Buy
11,200,666
+960,302
+9% +$13.7M ﹤0.01% 1786
2023
Q2 		$251M Sell
10,240,364
-27,098
-0.3% -$680K 0.01% 1342
2023
Q1 		$239M Buy
10,267,462
+172,961
+2% +$4.42M 0.01% 1356
2022
Q4 		$255M Buy
10,094,501
+166,085
+2% +$4.07M 0.01% 1297
2022
Q3 		$191M Buy
9,928,416
+1,731,172
+21% +$44M 0.01% 1412
2022
Q2 		$209M Buy
8,197,244
+438,847
+6% +$10.2M 0.01% 1398
2022
Q1 		$200M Buy
7,758,397
+428,266
+6% +$12.7M ﹤0.01% 1562
2021
Q4 		$307M Buy
7,330,131
+109,814
+2% +$4.3M 0.01% 1336
2021
Q3 		$314M Buy
7,220,317
+958,060
+15% +$41.5M 0.01% 1293
2021
Q2 		$296M Buy
6,262,257
+324,143
+5% +$14.7M 0.01% 1358
2021
Q1 		$304M Buy
5,938,114
+67,996
+1% +$3.66M 0.01% 1295
2020
Q4 		$157M Buy
5,870,118
+336,439
+6% +$10.9M ﹤0.01% 1604
2020
Q3 		$190M Buy
5,533,679
+5,173,792
+1,438% +$223M 0.01% 1316
2020
Q2 		$14.7M Buy
359,887
+182,567
+103% +$6.13M ﹤0.01% 2570
2020
Q1 		$6.08M Buy
177,320
+7,451
+4% +$200K ﹤0.01% 2873
2019
Q4 		$2.14M Buy
+169,869
New +$2.28M ﹤0.01% 3432

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
GP
GSK plc London $602M AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Group's VIR Position: Q4 2025 in Review

Vanguard Group reduced its Vir Biotechnology (VIR) stake by 2% in Q4 2025, selling an estimated $1.49M and leaving 12,548,944 shares worth $75.7M. The position accounts for ﹤0.01% of the portfolio, ranked #1973.

Vanguard Group first reported a position in VIR in Q4 2019 and has held it in 25 quarters since. The position peaked at $314M in Q3 2021. 218 funds tracked by Wall St. Rank hold VIR as of Q4 2025.

  • Vanguard Group held 12,548,944 shares of Vir Biotechnology worth $75.7M as of Q4 2025.
  • Vanguard Group sold 250,437 Vir Biotechnology shares in Q4 2025, an estimated $1.49M.
  • Vir Biotechnology made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #1973 holding.
  • Vanguard Group first reported a position in Vir Biotechnology in Q4 2019 and has held it in 25 quarters since.
  • Vanguard Group's Vir Biotechnology position peaked at $314M in Q3 2021.
  • 218 funds tracked by Wall St. Rank held Vir Biotechnology as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.